Evidence map›Paper›PMID 39668560›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Modified human mesenchymal stromal/stem cells restore cortical excitability after focal ischemic stroke in rats.

Barbara Klein, Agnieszka Ciesielska, Patricia Morán Losada, Anna Sato, Sajita Shah-Morales, Jeremy B Ford, Bryan Higashikubo, Dale Tager, Alexander Urry, Juliane Bombosch and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. "Time Is Brain" - for Cell Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Delayed Transplantation of Neural Stem Cells Improves Initial Graft Survival after Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Barbara KleinSanBio, Inc., Oakland, CA, USA. Electronic address: barbara.klein@outlook.com.
Agnieszka CiesielskaGladstone Institute of Neurological Disease, San Francisco, CA, USA; University of California, San Francisco, Department of Neurology, and the Kavli Institute for Fundamental Neuroscience, San Francisco, CA, USA.
Patricia Morán LosadaSanBio, Inc., Oakland, CA, USA.
Anna SatoSanBio, Inc., Oakland, CA, USA.
Sajita Shah-MoralesSanBio, Inc., Oakland, CA, USA.
Jeremy B FordGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Bryan HigashikuboGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Dale TagerGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Alexander UrryGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Juliane BomboschSanBio, Inc., Oakland, CA, USA.
Wei-Cheng ChangSanBio, Inc., Oakland, CA, USA.
Yaisa Andrews-ZwillingSanBio, Inc., Oakland, CA, USA.
Bijan NejadnikSanBio, Inc., Oakland, CA, USA.
Zuha WarraichSanBio, Inc., Oakland, CA, USA.
Jeanne T PazGladstone Institute of Neurological Disease, San Francisco, CA, USA; University of California, San Francisco, Department of Neurology, and the Kavli Institute for Fundamental Neuroscience, San Francisco, CA, USA; University of California, San Francisco, Neurosciences Graduate Program, San Francisco, CA, USA. Electronic address: jeanne.paz@gladstone.ucsf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic modified bone marrow-derived human mesenchymal stromal/stem cells (hMSC-SB623 cells) are in clinical development for the treatment of chronic motor deficits after traumatic brain injury and cerebral ischemic stroke. However, their exact mechanisms of action remain unclear. Here, we investigated the effects of this cell therapy on cortical network excitability, brain tissue, and peripheral blood at a chronic stage after ischemic stroke in a rat model. One month after focal cortical ischemic stroke, hMSC-SB623 cells or the vehicle solution were injected into the peri-stroke cortex. Starting one week after treatment, cortical excitability was assessed ex vivo. hMSC-SB623 cell transplants reduced stroke-induced cortical hyperexcitability, restoring cortical excitability to control levels. The histology of brain tissue revealed an increase of factors relevant to neuroregeneration, and synaptic and cellular plasticity. Whole-blood RNA sequencing and serum protein analyses showed that intra-cortical hMSC-SB623 cell transplantation reversed effects of stroke on peripheral blood factors known to be involved in stroke pathophysiology. Our findings demonstrate that intra-cortical transplants of hMSC-SB623 cells correct stroke-induced circuit disruptions even at the chronic stage, suggesting broad usefulness as a therapeutic for neurological conditions with network hyperexcitability. Additionally, the transplanted cells exert far-reaching immunomodulatory effects whose therapeutic impact remains to be explored.

Indexed as

Disease Models, AnimalIschemic StrokeMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCortical ExcitabilityHumansMaleRatsblood RNA sequencingcell therapycell transplantscortical hyperexcitabilitycortical network excitabilityex vivo electrophysiologyischemic strokemesenchymal stromal cellsSB623serum analysis

Identifiers

PMID39668560
PMCPMC11764858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.